FDA Delays Decision on AstraZeneca's Camizestrant Following Negative Adcomm Vote

Key Takeaways

• ODAC voted 3-6 against the benefit-risk of switching to camizestrant at ctDNA-detected ESR1 mutation before progression.
• SERENA-6 is registered as NCT04964934 and underpins the NDA filed after Breakthrough Therapy Designation.
• FDA accepted the NDA in July 2025 after ASCO 2025 and New England Journal of Medicine publication of SERENA-6.
• AstraZeneca did not disclose the length of the PDUFA extension in its delay notice.

What did the advisory committee decide on camizestrant?

In April 2026, FDA's Oncologic Drugs Advisory Committee voted 3 to 6 against the benefit-risk of the proposed first-line switch strategy.

The question focused on switching to camizestrant plus a CDK4/6 inhibitor after ESR1 mutation detection in ctDNA before radiographic progression.

Track upcoming oncology panels via the FDA advisory committee calendar.

Why is the SERENA-6 design controversial?

SERENA-6 switches endocrine partners when ESR1 mutations emerge on liquid biopsy, rather than waiting for imaging progression.

That molecular-switch paradigm is new to labeling debates even when PFS hazard ratios look strong.

Reviewers have asked whether earlier switching improves long-term outcomes versus standard progression-triggered changes.

What efficacy signal did SERENA-6 show?

SERENA-6 results were presented at ASCO 2025 and published in the New England Journal of Medicine family of oncology reports cited by the sponsor.

The Phase 3 protocol is public at ClinicalTrials.gov NCT04964934.

Secondary coverage commonly cites about a 56% reduction in risk of progression or death for the switch arm versus continued aromatase inhibitor therapy.

What happens during the FDA review extension?

AstraZeneca said FDA needs more time to review additional requested data supporting the NDA.

Those packages include ctDNA clearance analyses linked to longer-term efficacy outcomes presented around ASCO 2026.

Without a published new PDUFA date, commercial forecasts should keep a wide confidence band.

• ODAC vote: 3-6
• Trial ID: NCT04964934
• NDA accepted: July 2025

How should oral SERD competitors respond?

A negative ODAC vote raises the bar for any ESR1-guided early-switch claim.

Programs with progression-triggered designs may face fewer architecture objections.

Payers will wait for final labeling before rewriting prior authorization around ctDNA monitoring cadence.

What remains unproven for camizestrant?

FDA can still approve, reject, or request another review cycle despite ODAC advice.

Overall survival maturity and quality-of-life clarity remain debated.

Until an action letter posts, treat launch timing as unresolved.

How does Breakthrough Therapy status interact with a negative ODAC?

Breakthrough Therapy Designation accelerates FDA interaction but does not bind advisory committees or guarantee approval for camizestrant.

The May 2025 designation reflected earlier promise; the April 2026 vote shows residual doubt about the ESR1 switching paradigm.

Sponsors in similar settings should budget for additional analyses even after a clean Phase 3 progression-free survival readout.

What would a narrow label versus another review cycle mean?

FDA could still approve with labeling that tightly circumscribes ctDNA monitoring and switch timing for camizestrant.

Alternatively, the agency could request another cycle if the new clearance analyses do not answer survival and quality-of-life questions.

Commercial teams should prepare both a launch kit and a contingency plan for a longer delay.

Competitors should assume payers will demand explicit label language before paying for routine ESR1 liquid-biopsy surveillance.

For now, keep camizestrant models scenario-based: approval with tight ctDNA language, a multi-month delay, or a request for more outcomes data.

Short version: the ODAC vote raised the bar. Extra analyses must answer the switch-timing question in plain clinical terms.

Investors tracking camizestrant should calendar ASCO follow-ups and any FDA meeting minutes that clarify how much weight ctDNA clearance will carry in the final review.

Related NovaPharma coverage

• Celcuity gedatolisib breast cancer path
• Tissue vs blood TMB immunotherapy
• Breast cancer statistics worldwide

Frequently Asked Questions

Primary Sources

1. ClinicalTrials.gov: SERENA-6 (NCT04964934)
2. FDA advisory committee calendar
3. New England Journal of Medicine (SERENA-6 publication venue)